As an­oth­er an­tibi­otics biotech sinks in­to a cri­sis, warn­ings of a sec­tor ‘col­lapse’

An­oth­er an­tibi­otics com­pa­ny is scram­bling to sur­vive to­day, forc­ing the com­pa­ny’s found­ing CEO to ex­it in a re­or­ga­ni­za­tion that elim­i­nates its re­search ca­pa­bil­i­ties as the sur­vivors look to im­prove on mi­nus­cule sales of their new­ly ap­proved treat­ment. And the news — on top of an alarm­ing se­ries of fail­ures — spurred at least one fig­ure in the field to warn of a loom­ing col­lapse of the an­timi­cro­bial re­sis­tance re­search field.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER